echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Cardiovasc Diabetol: Different prognostic effects of cardiovascular disease and lower extremity amputation on the risk of all-cause mortality in long-term type 1 diabetes patients

    Cardiovasc Diabetol: Different prognostic effects of cardiovascular disease and lower extremity amputation on the risk of all-cause mortality in long-term type 1 diabetes patients

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Despite success in reducing the risk of diabetic complications over the past few decades, type 1 diabetes is still associated with an increased risk of premature death compared with matched individuals in the general populati.


    Background: Despite success in reducing the risk of diabetic complications over the past few decades, type 1 diabetes is still associated with an increased risk of premature death compared with matched individuals in the general populati.


    Objectives: In the current study, we explored whether there are prognostic differences between a history of CVD and nontraumatic LLA in terms of risk of all-cause mortality in patients with long-term type 1 diabet.


    METHODS: We used pooled data from prospective cohorts of SURGENE, GENEDIAB and GENES.


    Results: Among 1169 participants (55% male, age 40±13 years, duration of diabetes 23±11 years), 49 (2%), 62 (3%) and 20 (7%) were affected, respective.


    Table 1 Baseline participant characteristics by incidence of all-cause mortality during follow-up

    Figure 1 Kaplan Meier curve estimates of survival based on baseline history of cardiovascular disease (CVD) and lower extremity amputation (LLA): no cardiovascular disease (green line), cardiovascular disease only (red line), LLA only (blue line), and cardiovascular disease Disease and LLA (black lin.


    Figure 1 Kaplan Meier curve estimates of survival based on baseline history of cardiovascular disease (CVD) and lower extremity amputation (LLA): no cardiovascular disease (green line), cardiovascular disease only (red line), LLA only (blue line), and cardiovascular disease Disease and LLA (black lin.


    Table 2 Risk of all-cause mortality with history of cardiovascular disease or/and LLA at baseline during follow-up

    Conclusions: Cardiovascular disease and LLA caused a similar mortality burden in the type 1 diabetes populati.


    Conclusions: Cardiovascular disease and LLA caused a similar mortality burden in the type 1 diabetes populati.


    Original source: Camoin M, Velho G, Saulnier PJ, et .
    Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabet.
    Cardiovasc Diabetol 2022 May 09; 21(1) Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabet.
    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.